23 1 () 2
10 15 10 15 10 50 12 3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
1, Mohamed Nassef 2, 2, 3, 3, 4, 1, 1, 1, 1 1, 2, 3, 4 19
20
ü 21
22
23
24
25
(PET ) 68 Ga (t 1/2 = 68 min, ) PET Ga-DOTA 68 Ga 67 Ga(t 1/2 = 3.3 day) DOTA-(Asp) n (n = 2, 5, 8, 11, or 14) Fmoc 67 GaCl 3 67 Ga-DOTA-(Asp) n (HA) 67 Ga-DOTA-(Asp) n HA HA 67 Ga-DOTA-(Asp) n HA 67 Ga-DOTA-(Asp) 11, 14 99m Tc-HMDP / 67 Ga-DOTA-(Asp) n PET 26
27
28
29
Rapamycin IL-2 (IL-2R) T CD4 + T CD8 + T CFSE in vitro T CD4 + T CD8 + T rapamycin CFSE T Concanavalin A (ConA)PMA/ionomycin (PMA/iono) CD3 48hr rapamycin 24hr IL-2R CD4 + T CD8 + T flow cytometry CD4 + T CD8 + T rapamycin ConA CD3 PMA/iono CD4 + T CD8 + T 24hr IL-2R CD4 + T CD8 + T PMA/iono CD8 + T 48hr PMA/iono CD8 + T CD4 + T CD8 + T IL-2R PMA/iono CD8 + T rapamycin TCR PKCCa 2+ /CNRas/Raf/MAPK 3 ConA CD3 TCR PMA/iono PKC Ca 2+ /CN CD4 + T CD8 + T TCR CD8 + T PKCCa 2+ /CN CD4 + T Ras/Raf/MAPK 30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
2 49
50
R 1 HO R 1 = (HO) 3 O OR N R 2 = -C(CH 3 ) 2 OH R 1 = R 2 = NH N Bu-n N HN Bu-n n N N N R 2 Bu-n 51
1,4-2 1) Okamoto, T.; Oka, S. J. Org. Chem. 1984, 49, 1589 52
53
54
55
56
57
58
59